A Phase 1 Open-label, Single Ascending Dose Study of ABA-101 in Participants With Progressive Multiple Sclerosis
Latest Information Update: 15 Mar 2025
At a glance
- Drugs ABA 101 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; First in man
- Sponsors Abata Therapeutics
- 24 Sep 2024 Planned initiation date changed from 1 Sep 2024 to 1 Oct 2024.
- 24 Sep 2024 Status changed from not yet recruiting to recruiting.
- 23 Aug 2024 Status changed to not yet recruiting.